Mitochondrial Pyruvate Carrier Inhibition Mitigates Murine Chronic Graft Versus Host Disease By Attenuating the Germinal Center Reaction

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potent therapy for many hematopoietic diseases and malignancies. However, the long-term efficacy of allo-HSCT is limited by the development of chronic graft versus host disease (cGVHD). During cGVHD, interactions between donor-deriv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2023-11, Vol.142 (Supplement 1), p.459-459
Hauptverfasser: Mohamed, Fathima A, Rhee, Stephanie Y, Ly, Joanna, Aguilar, Ethan G, Melin, Haley, Sage, Peter T, Schumacher, Tanner, Thangavelu, Govindarajan, Zaiken, Michael C, Liu, Juan, Mereddy, Venkatram, Locasale, Jason W, Blazar, Bruce R
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potent therapy for many hematopoietic diseases and malignancies. However, the long-term efficacy of allo-HSCT is limited by the development of chronic graft versus host disease (cGVHD). During cGVHD, interactions between donor-derived T follicular helper cells (TFH) and germinal center B cells (GCB) result in the production of alloreactive class-switched affinity-matured antibodies that attack host tissues, causing multi-organ damage and tissue fibrosis. Novel treatment approaches are warranted to treat cGVHD since it is often refractory to current broad immune suppressive drugs. In this study we sought to delineate the metabolic dependencies of germinal center (GC) immune cells to discover new strategies to treat active murine cGVHD. We utilized a multi-organ mouse model of cGVHD that includes bronchiolitis obliterans (BO), a severe cGVHD manifestation seen in the clinic. Toward that end, B10.BR (H2 k) recipients received myeloablative conditioning with cyclophosphamide and total body irradiation before receiving MHC mismatched C57BL/6 (H2 b) donor T cell depleted bone marrow with (cGVHD) or without (BM only control) a low dose of splenic T cells. First, we sought to assess the metabolic dependencies of TFH during cGVHD progression through Seahorse metabolic flux assays. TFH sorted early (D28) from cGVHD mice were highly glycolytic with an increased extracellular acidification rate (ECAR) and less reliant on oxidative phosphorylation (OXPHOS) as reflected by a decreased oxygen consumption rate (OCR). However, TFH sorted later (D49) from cGVHD mice demonstrated a dramatic shift in their metabolic profile to a decreased ECAR and an increased OCR indicating a transition from glycolysis towards OXPHOS as disease progresses. To understand which substrates are driving increased OXPHOS and to identify promising metabolic targets, we performed unbiased metabolomics of sort purified TFH from BM only and cGVHD mice on D49 post-transplantation (Fig A). Among the top fifty differential metabolites, cGVHD TFH had a decreased abundance of anaplerotic amino acids (serine, glutamine) and an increased abundance of multiple breakdown products of anaplerotic amino acids (tryptophan, leucine), indicative of increased replenishment of tricarboxylic acid (TCA) cycle intermediates. Notably these metabolomics data showed a decreased abundance of glutamine which is consistent with an increase in glutaminolysis, v
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2023-185200